News from QIAGEN N.V. A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

Jan 31, 2018, 16:10 ET QIAGEN Reports Results for Fourth Quarter and Full-year 2017, Announces STAT-Dx Acquisition and New $200 Million Share Repurchase

- Solid Q4 results as QIAGEN achieves full-year 2017 targets: - Q4 2017: Net sales $396.9 million (+8% actual, +5% CER);...


Jan 31, 2018, 16:09 ET QIAGEN Enters into Agreement to Acquire STAT-Dx, Plans to Launch a Next-Generation, Fully Integrated Multiplex Platform for Syndromic Disease Testing

QIAGEN N.V. (NYSE: QGEN) (Frankfurt Prime Standard: QIA) announced today it has entered into an agreement to acquire STAT-Dx, a privately-held...


Jan 23, 2018, 16:05 ET QIAGEN Receives FDA Clearance for First-Ever JAK2 Test for Use in Diagnosis of Additional Myeloproliferative Neoplasms

QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that it has received clearance for its ipsogen JAK2 RGQ PCR Kit (ipsogen JAK2...


Jan 18, 2018, 16:05 ET QIAGEN Receives FDA Approval to Expand Use of EGFR Test in Lung Cancer

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that the U.S. Food and Drug Administration (FDA) has approved a PMA...


Jan 18, 2018, 05:41 ET QIAGEN N.V. to Report Fourth Quarter and Full Year of 2017 Results

QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) plans as previously announced to release its report on results for the fourth quarter and...


Jan 08, 2018, 02:00 ET QIAGEN adds to Growth Momentum in Next-Generation Sequencing with 2018 Plans for Significant Portfolio Enhancements

- Goal set to exceed $140 million of NGS-related sales in 2018, up from over $115 million in 2017 - New Enterprise Genomics...


Jan 08, 2018, 02:00 ET QIAGEN and DiaSorin Partner to Offer Fully Automated Tuberculosis Detection With QuantiFERON-TB Gold Plus Available on LIAISON Analyzer Systems

- QIAGEN's QuantiFERON-TB customers to gain access to fully automated workflow solution - DiaSorin to add novel content to...


Dec 22, 2017, 16:15 ET QIAGEN to Take Impairment on Deferred Tax Assets, Informs on Expected Impacts of New U.S. Tax Law and Other Changes in Global Tax Environment

QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) announces that, mainly as a consequence of the new U.S. tax legislation, it will take an...


Dec 15, 2017, 16:05 ET QIAGEN and Oxford Immunotec Settle Patent Infringement Lawsuit

QIAGEN N.V. (NASDAQ: QGEN, Frankfurt Stock Exchange: QIA) and Oxford Immunotec Ltd. (NASDAQ: OXFD) announced today that they have reached a...


Dec 08, 2017, 16:05 ET QIAGEN to Transfer U.S. Listing of Global Shares to NYSE

QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced that it is transferring the U.S. listing of its global shares to the New...


Nov 15, 2017, 16:05 ET QIAGEN Advances Precision Medicine by Automating Guidelines on Cancer Variants in Industry-leading QIAGEN Clinical Insight Software

QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today launched enhancements in its QIAGEN Clinical Insight (QCI) bioinformatics software...


Nov 14, 2017, 16:17 ET QIAGEN's GeneReader NGS System Delivers Accuracy and Ease of Use for Clinical Research in Oncology

QIAGEN N.V. (NASDAQ: QGEN) (Frankfurt Prime Standard: QIA) today announced new studies highlighting the outstanding analytical performance and...


Nov 13, 2017, 16:02 ET QIAGEN Celebrates Surpassing 2,000 Cumulative Placements of QIAsymphony

QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced the 2,000th placement of QIAsymphony, the leading Sample to Insight...


Nov 06, 2017, 16:05 ET QIAGEN Reports Results for Third Quarter and First Nine Months of 2017

- Solid Q3 2017 performance in line with full-year ambitions: - Net sales $364.0 million (+7% actual, +7% CER); adjusted net sales...


Oct 24, 2017, 11:25 ET QIAGEN and ICMP Launch Next-Generation DNA Testing Solutions for Identifying Missing Persons

The International Commission on Missing Persons (ICMP) today announced the launch of a cutting-edge next-generation sequencing (NGS) workflow...


Oct 19, 2017, 16:36 ET QIAGEN Announces High Accuracy of Bioinformatics Solutions in Women's Health Genetic Screening

QIAGEN (NASDAQ: QGEN; Frankfurt Stock Exchange: QIA) today announced the results of a study evaluating the accuracy of the QIAGEN Clinical Insight...


Oct 16, 2017, 06:20 ET QIAGEN N.V. to Report Third Quarter and First Nine Months of 2017 Results

QIAGEN N.V. (NASDAQ: QGEN) (Frankfurt: QIA) plans as previously announced to release its report on results for the third quarter and first nine...


Oct 12, 2017, 16:05 ET QIAGEN Bioinformatics and NGS Solutions Enable Genomic Breakthroughs

QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced that its Sample to Insight solutions, from next-generation sequencing...


Oct 09, 2017, 16:05 ET QIAGEN and CENTOGENE to Collaborate in Bioinformatics for Genetic Diseases

QIAGEN (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) and CENTOGENE AG today announced a collaboration and co-marketing agreement to provide...


Oct 05, 2017, 16:05 ET QIAGEN Launches Fourth-generation QuantiFERON®-TB Gold Plus in the U.S.

QIAGEN (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced the U.S. launch of QuantiFERON®-TB Gold Plus (QFT®-Plus), the fourth...


Oct 02, 2017, 16:05 ET QIAGEN Achieves ISO Certification for State-of-the-art Quality in Forensics

QIAGEN (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced that its manufacturing and supply chain for consumables and other products...


Aug 21, 2017, 16:05 ET QIAGEN and Clinical Genomics Partner on Liquid Biopsies to Monitor Patients for Recurrence of Colorectal Cancer

QIAGEN (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) and Clinical Genomics, a private company developing evidence-based diagnostic tools for...


Jul 27, 2017, 11:16 ET QIAGEN Reports Results for Second Quarter and First Half of 2017

- Strong Q2 2017 results reaffirm QIAGEN on track to achieve full-year goals: - Net sales $349.0 million (+4% actual); adjusted net...


Jul 13, 2017, 04:02 ET QIAGEN N.V. to Report Second Quarter and First Half of 2017 Results

QIAGEN N.V. (Nasdaq: QGEN) (Frankfurt: QIA) plans as previously announced to release its report on results for the second quarter and first half of...


Jun 22, 2017, 08:04 ET French health system approves reimbursement of QIAGEN's QuantiFERON latent TB test

QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced that France's Ministry of Health and Social Affairs has approved...